Prostate cancer is now the most common cancer diagnosed in American males and the second leading cause of cancer deaths in the United States. When caught early and treated appropriately, the majority of patients can be cured from their cancer. The Prostate and Urologic Cancers Program at Smilow Cancer Hospital evaluates, diagnoses and treats cancers of the prostate, bladder, kidneys and testicles.
At the Prostate and Urologic Cancers Program, we offer patients easy access to specialized care for these cancers. As a multispecialty program, we are dedicated to providing cutting-edge technology for the evaluation, diagnosis, and treatment of prostate cancer and other urologic cancers.
Why Smilow Cancer Hospital for Prostate and Urologic Cancers
Prostate cancer is relatively common, yet very few institutions specialize in the treatment of it, as well as in the treatment of other urologic cancers (bladder, kidney and testicular cancer). Our multidisciplinary team of experts diagnose and treat patients with these cancers. The team meets and discusses cases among all subspecialties. We have a unique immunotherapy program for renal cell cancer and conduct considerable research in prostate, bladder and renal cancers.
Since every specialty exists within one clinical practice, an important advantage to the patient is our ability to form a comprehensive, disease-based multispecialty team to treat prostate, bladder, kidney, and testicular cancers. The program design coordinates the diagnosis, evaluation, and treatment through the collaboration of specialty physicians who have nationally and internationally recognized expertise in these cancers.
Specialties involved include medical oncology, radiation oncology, surgical oncology, pathology, and diagnostic imaging. Physicians meet regularly to discuss every patient's care and to develop a comprehensive treatment plan unique for each patient, in consultation with the patient's referring physician. We find this coordination and collaboration to be efficient and, in turn, it raises the medical management to the highest quality.
Not only does the team provide a complete range of standard treatments, but also available are medical and surgical approaches not found elsewhere in Connecticut. This includes non-invasive surgical techniques with laparoscopic surgery, precision guided intensity modulated radiotherapy (IMRT), combined modality approaches with chemotherapy and radiotherapy, and novel experimental therapies.
The first to offer IMRT in 1998, Yale-New Haven's Radiation Oncology services has the longest experience in Connecticut using IMRT. Since then, we have accumulated a vast experience with the IMRT and we have continued to enhance the techniques to deliver IMRT, which has led to extremely minimal complication rates of 1 percent. Patients who are cared for through the Prostate and Urologic Cancers Program and need radiation therapy as a component of their prescribed treatment can feel confident that they are receiving the highest quality care from the most experienced team of radiation oncologists in the State.
Our surgical center receives referrals for all malignancies of the testes, bladder, prostate, and kidney. Urologic laparoscopic procedures include: laparoscopic nephrectomy and partial nephrectomy and laparascopic lymph node dissection for testes cancer. Cryoablation (freezing the tumor) is available for appropriate kidney tumors. Ureteroscopic laser ablation for urothelial tumors is also used for upper tract lesions. In addition, Yale-New Haven Hospital has added the daVinci robotic surgical technology for radical prostatectomy.
Our patients have access to caregivers who help them cope with the physical, emotional, and psychological issues related to these cancers. The extended team includes a health educator, social worker and a dietitian; and complementary therapists.
Learn more about the Prostate and Urologic Cancers Program of Yale Cancer Center.
Learn more about Urology at Yale-New Haven Hospital.
Call 203.200.4822 to find out more about the Prostate and Urologic Cancers Program at Smilow Cancer Hospital.